But, again it was up for its preventive effect on heart stroke and was used in post-heart attack patients primarily for prevention of dangerous clot formation. It keeps blood in a more fluid state by preventing the action of platelets from wrongful aggregation.
Much work in the recent years have proved that the low cost drug is also helpful in preventing many cancers as well as early diagnosis of many.
Still, the prescription of the drug is on the basis of weighing the necessity against possible side effects.
Now, scientists from The City College of New York have developed a new aspirin compound that has great promise to be not only an extremely potent cancer-fighter, but even safer than the classic drug.
|New Aspirin with Hydrogen Sulfide and Nitric Oxide|
The new molecule is a hybrids of aspirin (ASA), bearing both nitric oxide (NO) and hydrogen sulfide (H2S)-releasing moieties, designated as NOSH-Aspirin.
The new aspirin has cancer inhibiting properties on cell lines of adenomatous (colon, pancreatic, lung, prostate), epithelial (breast), and lymphocytic (leukemia) origin.
This compound is also devoid of many cellular toxicity due to presence of nitric oxide and hydrogen sulfide.
The new drug only has been tested in mice, and has to undergo many tests before advocated for human consumption that may take years.